Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.

• Authors: MEJSTŘÍKOVÁ Kateřina; KALINA T.; VOLEJNÍKOVÁ J.; ŠTĚRBA Jaroslav; FROŇKOVÁ E.; JABALI Y.; ZDRÁHALOVÁ K.; MIHÁL V.; KALINA T.; ŠTĚRBA Jaroslav; JABALI Y.; MIHAL V.; BLAZEK B.; CERNA Z.; PROCHAZKOVA Daniela; HAK Jiří; ZEMANOVÁ Zuzana; JAROSOVA M.; OLTOVA Alexandra; SEDLACEK P.; SCHWARZ J.; ZUNA Jan; TRKA Jan; STARY Jan; HRUSAK O.
• Year of publication: 2010
• Type: Article in Periodical
• Magazine / Source: Hematologica - The Hematology Journal
• MU Faculty or unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3324/haematol.2009.014506
• Field: Oncology and hematology
• Keywords: pediatric acute lymphoblastic leukemia; pediatric acute myeloid leukemia; mixed phenotype leukemia; biphenotypic leukemia; aberrant antigens; cytometry; acute hybrid leukemia
• Description: Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma. The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage markers. Discussions surrounding it have focused on scoring details, and information is limited regarding its biological, clinical and prognostic significance. The recent World Health Organization classification is simpler and could replace the EGIL scoring system after transformation into unambiguous guidelines.